Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company"), is announcing its intention to commence a substantial issuer bid (the "Offer" or "SIB") pursuant to which the Company will offer...

(All figures are presented in U.S. dollars) Strong growth capital available with $36.3 million in cash and cash equivalents Net income increased by 32% year-over-year to $5.7 million EPS increased...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the second quarter of 2023 on Thursday, August 10, 2023. The...

Significant regulatory milestone reached by Moberg, paving the way for their commercial launch across 13 countries in Europe Cipher holds exclusive Canadian rights to MOB-015 and sees the approval...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before...

(All figures are presented in U.S. dollars) Cash on hand grew by $4.6 million to $33.4 million EPS increased 25% year-over-year to $0.10 Adjusted EBITDA1 of $3.2 million was higher than Q1 2022...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the first quarter of 2023 on Thursday, May 11, 2023. The Company...

Mississauga, Ontario--(Newsfile Corp. - April 18, 2023) - Cipher Pharmaceuticals (TSX: CPH), a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage...

(All figures are in U.S. dollars) Product revenue increased 9% to $12.5 million in 2022 EBITDA of $12.0 million, relatively flat YoY Cash at December 31, 2022 was $28.8 million (CDN$39 million) or...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial results for the three and twelve months ended December 31, 2022 after market...